Dear Reader

As we reach the final issue of *Drugs in R&D* for 2011, we hope that you have found the articles published throughout the year to be both interesting and informative. The editors and publishing staff have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues in the field of research and development in 2012.

The high quality of Adis Journals was further recognized in the new ISI impact factors (IFs) for 2010, with the majority of our titles making strong IF gains over 2009. *Drugs in R&D* (1.707), re-launched in 2010 as Adis' first fully open-access MEDLINE-indexed journal, increased by 26%. The most impressive gains were made by *Sports Medicine* (5.072), with a 63% increase making it the highest ranked title in its field, and *PharmacoEconomics* (3.44), increasing by 34% to become the leading health outcomes research journal. Other stand-out performers include *CNS Drugs* (4.497) and *BioDrugs* (4.192), with increases of 16% and 20%, respectively.

Another significant milestone was reached by *The Patient: Patient-Centered Outcomes Research*, with the journal achieving MEDLINE indexing this year. *The Patient* was launched by Adis in 2008 as the first journal dedicated to the needs, values and role of patients in healthcare decision making.

Last, but not least, we would like to say a big thank you to all the authors who have contributed articles to *Drugs in R&D* in the last 12 months. Without their hard work and diligence we would not have been able to publish the journal. The quality of published articles also reflects the significant time and effort dedicated by the peer reviewers who ensure that we continue to publish content of the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals who acted as referees for articles in *Drugs in R&D* in 2011:

*J. Agarwal*, India

*T. Bacun*, Croatia

*Marc Bardou*, France

*Mehmet Borazan*, Turkey

*Andrea Calcagno*, Italy

*N.A. Calcutt*, USA

*Luigi Celio*, Italy

*Stephen J. Clarke*, Australia

*H. Deshpande*, USA

*N. DiRenzo*, Italy

*N.J. Gibson*, USA

*Stefan Glück*, USA

*M. Goldman*, USA

*K. Hayashi*, Japan

*O. Heikinheimo*, Finland

*R.C. Hermida*, Spain

*N. Hunfeld*, the Netherlands

*Y. Kawano*, Japan

*Philippe R. Koninckx*, Belgium

*Charles J.L. la Porte*, Canada

*Shiu Kum Lam*, China

*M. Laryea*, Germany

*Andrew Latchman*, Canada

*Judith Lees*, Australia

*Y. Liang*, China

*Annika Malmstrom*, Sweden

*Mark J. McKeage*, New Zealand

*Stephan Meckel*, Australia

*G. Mijnhout*, the Netherlands

*F. Ng*, Hong Kong

*S. Oto*, Turkey

*Jose-Alberto Palma*, Spain

*Irene Pecorella*, Italy

*Ismene I.L. Petrakis*, USA

*Henry A. Punzi*, USA

*Bernhard Resch*, Austria

*Ana Ricobaraza*, Spain

*Brian I. Rini*, USA

*Christos Rizos*, Greece

*Stefano Rusconi*, Italy

*A. Sadato*, Japan

*Koravangattu Sankaran*, Canada

*M. Schul*, USA

*Robert Steigerwalt*, Italy

*Yi-Wen Tsai*, Taiwan, Province of China

*Yang Wang*, China

*D.G. Warr*, Canada

*George E. Woody*, USA

*P.K. Yeung*, Canada

We look forward to your continued support in 2012 and to bringing you first-class content from around the globe. With best wishes from the staff of *Drugs in R&D* and all at Adis, a Wolters Kluwer business.
